Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting ivps42019-02-19T17:33:44+00:00February 22nd, 2019|Press Release| Read More
Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation ivps42019-02-19T15:59:12+00:00February 20th, 2019|Press Release| Read More
Achieve Announces Update on Cytisinicline Clinical Development Program ivps42018-12-17T17:56:19+00:00December 18th, 2018|Press Release| Read More
Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update ivps42018-11-06T04:15:59+00:00November 7th, 2018|Press Release| Read More
Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018 ivps42018-10-29T16:03:57+00:00October 31st, 2018|Press Release| Read More
Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation ivps42018-10-29T16:55:13+00:00October 30th, 2018|Press Release| Read More
Achieve Announces Pricing of $5.6 Million Registered Direct Offering ivps42018-10-01T08:50:52+00:00October 1st, 2018|Press Release| Read More
Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed and Fasted Subjects ivps42018-09-26T14:26:57+00:00September 27th, 2018|Press Release| Read More
Achieve to Present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 ivps42018-09-26T12:36:56+00:00September 26th, 2018|Press Release| Read More
Achieve Announces Positive Cytisine Data Published in International Journal of Drug Policy ivps42018-09-17T12:46:46+00:00September 18th, 2018|Press Release| Read More